Nintedanib is under clinical development by Austhera BioSciences and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nintedanib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nintedanib (KNIN) is under development for the treatment of idiopathic pulmonary fibrosis. The drug candidate is administered through sublingual route and developed based on kinetisol technology.
Austhera BioSciences overview
Austhera BioSciences is a pharmaceutical development company that develops transformative drug candidates and novel chemical entities for the treatment of cancer and rare diseases. Austhera BioSciences is headquartered in Georgetown, Texas, the US.
For a complete picture of Nintedanib’s drug-specific PTSR and LoA scores, buy the report here.